Not Losing Weight on GLP cover art

Not Losing Weight on GLP

Not Losing Weight on GLP

Listen for free

View show details

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary
Read the Full Clinical Guide & Dosage Chart: https://losingweightrx.com/blog/why-am-i-not-losing-weight-on-glp-1 Check Doctor Eligibility & Start for $49/mo Flat: https://losingweightrx.com/ Struggling with a GLP-1 plateau? Learn why weight loss stalls on Ozempic or Wegovy, the role of metabolic adaptation, and how to kickstart progress. Video Chapters & Episode Timestamps: 0:00 - Introduction & Clinical Overview 0:45 - Mechanism of Action & Incretin Signaling (GLP-1 / GIP Receptors) 1:30 - Recommended Titration Schedules & Dosage Safety Milestones 2:15 - Clinical Trial Benchmarks & Realistic Weight Loss Timelines 3:00 - Transparent Cost Breakdown & Avoiding Hidden Telehealth Fees 3:45 - Key Patient Takeaways, FAQs & How to Get Started In-Depth Clinical Guide & Key Monograph Takeaways: [Clinical Analysis] Why Am I Not Losing Weight on GLP-1?: If you have stopped losing weight or are experiencing a weight stall on GLP-1 receptor agonist therapy, it is usually the result of your body's counter-regulatory metabolic adaptations, sub-therapeutic dosing, or a progressive reduction in receptor sensitivity. Glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro... [Clinical Analysis] What Is a True GLP-1 Plateau vs. a Normal Weight Loss Pause?: A true clinical GLP-1 plateau is defined as a complete cessation of weight loss for four consecutive weeks or longer at a stable therapeutic dose, whereas a normal weight loss pause is a temporary metabolic reset lasting one to three weeks. During a normal weight loss journey, body weight does not decline linearly. Transient water retention, shifts in glycogen storage, and mino... [Clinical Analysis] How Does Metabolic Adaptation Cause Weight Loss to Stall?: Metabolic adaptation, or adaptive thermogenesis, causes weight loss to stall by lowering your resting energy expenditure more than can be explained by changes in body mass alone [1]. This process is governed by mathematical principles of energy balance. In 2011, researchers publishing in The Lancet quantified how the human body adapts to a persistent calorie deficit [1]. As bod... [Clinical Analysis] How Do Down-Regulation of GLP-1 Receptors and cAMP Signaling Affect Satiety?: Down-regulation of GLP-1 receptors and alterations in cAMP signaling in the area postrema affect satiety by reducing the brain's sensitivity to the medication, which can lead to the gradual return of hunger and food noise [3]. The molecular pharmacology of GLP-1 receptor agonists explains how patients develop a tolerance to these drugs over time [3]. GLP-1 receptors are G-prote... [Clinical Analysis] Why Does Muscle Loss Contribute to a Metabolic Stall on GLP-1?: Muscle loss contributes to a metabolic stall on GLP-1 by reducing your metabolically active lean mass, which directly lowers your resting metabolic rate and slows down the overall rate of calorie burning. The clinical impact of rapid weight loss on body composition was documented in the STEP 1 clinical trial of semaglutide [2]. A body composition substudy within this landmark t... [Clinical Analysis] What Are the Clinical Solutions to Kickstart Weight Loss on a GLP-1?: The clinical solutions to kickstart weight loss on a GLP-1 include optimizing your dosage, performing structured resistance training, increasing protein titration, and addressing metabolic adaptation [2]. Many weight loss stalls occur because the patient has stopped titrating before reaching the maximum tolerated maintenance dose. Clinical guidelines outline a structured titrat... Losing Weight RX Direct-to-Patient Advantage: - Compounded Semaglutide: $49/mo introductory clinical pricing with doctor care - Compounded Tirzepatide: Transparent monthly rates with zero dose-escalation markups - Legitimate US 503A Pharmacy Fulfillment: Third-party certificate of analysis (COA) batch testing - No Insurance Red Tape: No prior authorizations, no pharmacy line waits, free express delivery Pharmacological Mechanism & Incretin Science: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are native incretin hormones secreted by the enteroendocrine L-cells and K-cells of the gastrointestinal tract in response to nutrient intake. In pharmacological doses, synthetic dual and single agonists bind to high-affinity receptors located in the pancreatic beta-cells, enteric nervous system, and key hypothalamic nuclei governing energy homeostasis. This triggers glucose-dependent insulin secretion, inhibits unphysiological glucagon surge, and delays gastric emptying rate. Clinically, patients experience significant reduction in subjective appetite cravings, reduced food-seeking impulses ('food noise'), and accelerated satiety onset after modest caloric consumption. vidualized consultation and clinical approval by a state-licensed healthcare provider. Prescri
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.